Cardiovascular disease: Pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke

被引:28
作者
Castelli, WP [1 ]
机构
[1] Framingham Cardiovasc Inst, Framingham, MA 01702 USA
关键词
cardiovascular disease; lung cancer; oral contraceptives; smoking;
D O I
10.1016/S0002-9378(99)70695-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Smoking increases the risk of lung cancer and cardiovascular disease among persons of both sexes; The risk of cardiovascular disease is further increased among users of oral contraceptives who smoke, particularly those who are greater than or equal to 35 years old or carry the coagulation factor V Leiden mutation. Other important cardiovascular disease risk factors in women include waist/hip girth ratio >0.8, high concentration of low-density lipoprotein cholesterol (>115 mg/dL), high triglyceride level (greater than or equal to 150 mg/dL) with low concentration of high-density lipoprotein cholesterol (less than or equal to 45 mg/dL), high ratio of total cholesterol/high-density lipoprotein (4.0), high ratio of low-density lipoprotein/high-density lipoprotein (3.0), glucose values greater than or equal to 100 mg/dL, hypertension, lack of physical activity, and high-fat diet. Most excess cardiovascular disease among users of oral contraceptives is due to thrombosis (not atherosclerosis); studies indicate that the lower the oral contraceptive estrogen dose is, the lower is this risk. Oral contraceptives containing the third-generation progestins desogestrel and gestodene have been associated with greater risks of Venous thromboembolism than are associated with older progestins, although there is some controversy surrounding these findings.
引用
收藏
页码:S349 / S356
页数:8
相关论文
共 46 条
[1]   ORAL-CONTRACEPTIVES, LIPOPROTEINS, AND ATHEROSCLEROSIS [J].
ADAMS, MR ;
CLARKSON, TB ;
SHIVELY, CA ;
PARKS, JS ;
KAPLAN, JR .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (04) :1388-1393
[2]  
*AM COLL PHYS, 1994, ACP TASK FORC AD IMM, P1
[3]   THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION [J].
ANDERSON, TJ ;
MEREDITH, IT ;
YEUNG, AC ;
FREI, B ;
SELWYN, AP ;
GANZ, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :488-493
[4]   ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].
AUSTIN, MA ;
KING, MC ;
VRANIZAN, KM ;
KRAUSS, RM .
CIRCULATION, 1990, 82 (02) :495-506
[5]  
Barrett D H, 1994, Arch Fam Med, V3, P438, DOI 10.1001/archfami.3.5.438
[6]   HEMOSTATIC AND METABOLIC EFFECTS OF LOWERING THE ETHINYL-ESTRADIOL DOSE FROM 30 MCG TO 20 MCG IN ORAL-CONTRACEPTIVES CONTAINING DESOGESTREL [J].
BASDEVANT, A ;
CONARD, J ;
PELISSIER, C ;
GUYENE, TT ;
LAPOUSTERLE, C ;
MAYER, M ;
GUYGRAND, B ;
DEGRELLE, H .
CONTRACEPTION, 1993, 48 (03) :193-204
[7]   Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias [J].
Bloemenkamp, KWM ;
Rosendaal, FP ;
Büller, HR ;
Helmerhorst, FM ;
Colly, LP ;
Vandenbroucke, JP .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (01) :65-70
[8]   ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN [J].
BLOEMENKAMP, KWM ;
ROSENDAAL, FR ;
HELMERHORST, FM ;
BULLER, HR ;
VANDENBROUCKE, JP .
LANCET, 1995, 346 (8990) :1593-1596
[9]   THALLIUM 201 FOR ASSESSMENT OF MYOCARDIAL VIABILITY [J].
BONOW, RO ;
DILSIZIAN, V .
SEMINARS IN NUCLEAR MEDICINE, 1991, 21 (03) :230-241
[10]   PREVALENCE OF HYPERTENSION IN THE US ADULT-POPULATION - RESULTS FROM THE 3RD NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY, 1988-1991 [J].
BURT, VL ;
WHELTON, P ;
ROCCELLA, EJ ;
BROWN, C ;
CUTLER, JA ;
HIGGINS, M ;
HORAN, MJ ;
LABARTHE, D .
HYPERTENSION, 1995, 25 (03) :305-313